224 related articles for article (PubMed ID: 33176247)
1. Design strategies for long-acting anti-HIV pharmaceuticals.
Sang Y; Ding L; Zhuang C; Chen F
Curr Opin Pharmacol; 2020 Oct; 54():158-165. PubMed ID: 33176247
[TBL] [Abstract][Full Text] [Related]
2. Cabotegravir/Rilpivirine: the last FDA-approved drug to treat HIV.
Taki E; Soleimani F; Asadi A; Ghahramanpour H; Namvar A; Heidary M
Expert Rev Anti Infect Ther; 2022 Aug; 20(8):1135-1147. PubMed ID: 35596583
[TBL] [Abstract][Full Text] [Related]
3. Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials.
Rizzardini G; Overton ET; Orkin C; Swindells S; Arasteh K; Górgolas Hernández-Mora M; Pokrovsky V; Girard PM; Oka S; Andrade-Villanueva JF; Richmond GJ; Baumgarten A; Masiá M; Latiff G; Griffith S; Harrington CM; Hudson KJ; St Clair M; Talarico CL; Patel P; Cutrell A; Van Eygen V; D'Amico R; Mrus JM; Wu S; Ford SL; Chow K; Roberts J; Wills A; Walters N; Vanveggel S; Van Solingen-Ristea R; Crauwels H; Smith KY; Spreen WR; Margolis DA
J Acquir Immune Defic Syndr; 2020 Dec; 85(4):498-506. PubMed ID: 33136751
[TBL] [Abstract][Full Text] [Related]
4. Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).
Chounta V; Overton ET; Mills A; Swindells S; Benn PD; Vanveggel S; van Solingen-Ristea R; Wang Y; Hudson KJ; Shaefer MS; Margolis DA; Smith KY; Spreen WR
Patient; 2021 Nov; 14(6):849-862. PubMed ID: 34056699
[TBL] [Abstract][Full Text] [Related]
5. Rilpivirine long-acting for the prevention and treatment of HIV infection.
Ferretti F; Boffito M
Curr Opin HIV AIDS; 2018 Jul; 13(4):300-307. PubMed ID: 29794818
[TBL] [Abstract][Full Text] [Related]
6. The promise and pitfalls of long-acting injectable agents for HIV prevention.
Landovitz RJ; Kofron R; McCauley M
Curr Opin HIV AIDS; 2016 Jan; 11(1):122-8. PubMed ID: 26633643
[TBL] [Abstract][Full Text] [Related]
7. Long-Acting Injectable ART in Practice: A Mixed Methods Implementation Study Assessing the Feasibility of Using LAI ART in High Risk Populations and At Alternative Low Barrier Care Sites.
Fletcher L; Burrowes S; Sabin LL; McCann N; Khan GK; Ruiz-Mercado G; Johnson S; Kimmel SD; Pierre C; Drainoni ML
AIDS Patient Care STDS; 2024 May; 38(5):221-229. PubMed ID: 38656905
[TBL] [Abstract][Full Text] [Related]
8. Long-acting drugs and formulations for the treatment and prevention of HIV infection.
Flexner C; Owen A; Siccardi M; Swindells S
Int J Antimicrob Agents; 2021 Jan; 57(1):106220. PubMed ID: 33166693
[TBL] [Abstract][Full Text] [Related]
9. Development and Evaluation of Dissolving Microarray Patches for Co-administered and Repeated Intradermal Delivery of Long-acting Rilpivirine and Cabotegravir Nanosuspensions for Paediatric HIV Antiretroviral Therapy.
Moffatt K; Tekko IA; Vora L; Volpe-Zanutto F; Hutton ARJ; Mistilis J; Jarrahian C; Akhavein N; Weber AD; McCarthy HO; Donnelly RF
Pharm Res; 2023 Jul; 40(7):1673-1696. PubMed ID: 36224503
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of the long-acting regimen cabotegravir plus rilpivirine for the treatment of HIV-1 and its potential impact on adherence and viral transmission: A modelling study.
Parker B; Ward T; Hayward O; Jacob I; Arthurs E; Becker D; Anderson SJ; Chounta V; Van de Velde N
PLoS One; 2021; 16(2):e0245955. PubMed ID: 33529201
[TBL] [Abstract][Full Text] [Related]
11. Low Frequency of Drug-Resistant Variants Selected by Long-Acting Rilpivirine in Macaques Infected with Simian Immunodeficiency Virus Containing HIV-1 Reverse Transcriptase.
Melody K; McBeth S; Kline C; Kashuba AD; Mellors JW; Ambrose Z
Antimicrob Agents Chemother; 2015 Dec; 59(12):7762-70. PubMed ID: 26438501
[TBL] [Abstract][Full Text] [Related]
12. Formulation and pharmacology of long-acting rilpivirine.
Williams PE; Crauwels HM; Basstanie ED
Curr Opin HIV AIDS; 2015 Jul; 10(4):233-8. PubMed ID: 26049947
[TBL] [Abstract][Full Text] [Related]
13. Long-acting antiviral agents for HIV treatment.
Margolis DA; Boffito M
Curr Opin HIV AIDS; 2015 Jul; 10(4):246-52. PubMed ID: 26049949
[TBL] [Abstract][Full Text] [Related]
14. Cabotegravir in the treatment and prevention of Human Immunodeficiency Virus-1.
McPherson TD; Sobieszczyk ME; Markowitz M
Expert Opin Investig Drugs; 2018 Apr; 27(4):413-420. PubMed ID: 29633869
[TBL] [Abstract][Full Text] [Related]
15. Human immunodeficiency virus infection challenges: Current therapeutic limitations and strategies for improved management through long-acting injectable formulation.
Tanushree ; Sharma A; Monika ; Singh RP; Jhawat V
Rev Med Virol; 2024 Jul; 34(4):e2563. PubMed ID: 38886179
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic review of cabotegravir/rilpivirine long-acting antiretroviral injectable and implementation considerations at an HIV specialty clinic.
Howe ZW; Norman S; Lueken AF; Huesgen E; Farmer EK; Jarrell K; Mathis JE; Bonham KW; Hahn J
Pharmacotherapy; 2021 Aug; 41(8):686-699. PubMed ID: 34130357
[TBL] [Abstract][Full Text] [Related]
17. An evaluation of cabotegravir for HIV treatment and prevention.
Canetti D; Spagnuolo V
Expert Opin Pharmacother; 2021 Mar; 22(4):403-414. PubMed ID: 33112699
[No Abstract] [Full Text] [Related]
18. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.
Orkin C; Oka S; Philibert P; Brinson C; Bassa A; Gusev D; Degen O; García JG; Morell EB; Tan DHS; D'Amico R; Dorey D; Griffith S; Thiagarajah S; St Clair M; Van Solingen-Ristea R; Crauwels H; Ford SL; Patel P; Chounta V; Vanveggel S; Cutrell A; Van Eygen V; Vandermeulen K; Margolis DA; Smith KY; Spreen WR
Lancet HIV; 2021 Apr; 8(4):e185-e196. PubMed ID: 33794181
[TBL] [Abstract][Full Text] [Related]
19. Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long-acting cabotegravir and rilpivirine in clinical trials.
Patel P; Ford SL; Baker M; Meyer C; Garside L; D'Amico R; Van Solingen-Ristea R; Crauwels H; Polli JW; Seal C; Yagüe Muñoz I; Thiagarajah S; Birmingham E; Spreen WR; Baugh B; van Wyk J; Vannappagari V
HIV Med; 2023 May; 24(5):568-579. PubMed ID: 36411596
[TBL] [Abstract][Full Text] [Related]
20. Long-Acting Antiretrovirals: Where Are We now?
Nyaku AN; Kelly SG; Taiwo BO
Curr HIV/AIDS Rep; 2017 Apr; 14(2):63-71. PubMed ID: 28303548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]